Alyftrek for Australians

What is Alyftrek?

Alyftrek is a new medication taken as one dose a day to treat cystic fibrosis (CF) in people aged 6 and older with at least one responsive CFTR mutation – including the common F508del.

It’s a next-generation triple-combination CFTR modulator that targets the underlying cause of CF. By improving the function of the faulty CFTR protein, Alyftrek helps thin mucus, improve lung function, and reduce respiratory infections.

Why is this important?

– Alyftrek simplifies treatment with one dose a day.

– Clinical trials show significant improvements in lung function and quality of life.

– Many people are unable to take current treatments, and/or do not respond well to them.

– It offers a new option alongside existing treatments like Trikafta.

– This is the first time in three years the PBAC are considering a new treatment option for Australians with CF.

Advocating for Access:

Alyftrek and the Future of CF Care in Australia

In December 2024, the U.S. Food and Drug Administration (FDA) approved Alyftrek (ivacaftor, tezacaftor, and deutivacaftor), a next-generation triple therapy for cystic fibrosis that builds on the success of existing modulators. The U.K. Medicines and Healthcare Products Regulatory Agency also approved Alyftrek in March 2025. These approvals represent major steps forward in the global fight against CF, offering the potential for improved outcomes and quality of life for many living with the condition.

At Cystic Fibrosis Australia, we believe that all Australians living with CF deserve equal access to the latest and most effective treatments – no matter where they live or what their genotype may be. That’s why we are actively advocating to ensure Alyftrek is evaluated, approved, and listed on the Pharmaceutical Benefits Scheme (PBS) as quickly as possible, so Australian families are not left waiting for the therapies that could change, or even save, lives.

Our role doesn’t end with awareness. We are engaged at every level, from direct government submissions to amplifying the voices of our community through consumer comments and public consultations.

#alyftrekforaustralians

We need your help.

Time is running out. We have until 28 May 2025 to show the Pharmaceutical Benefits Advisory Committee (PBAC) just how vital access to Alyftrek is for Australians living with cystic fibrosis.

This is our chance – your chance – to make a real difference.

By submitting a consumer comment, you’re not just filling out a form, you’re helping to shape the future of CF treatment in Australia. Every voice counts, and yours could be the one that tips the scale.

We need to show decision-makers the urgency, the impact, and the human stories behind the statistics.

Please act now. Help us fight for access to life-changing medication, and ensure everyone in our community has access to the treatments and therapies they need to lead full and healthy lives.